Comparative Pharmacology
Head-to-head clinical analysis: ELASE CHLOROMYCETIN versus THERMAZENE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELASE CHLOROMYCETIN versus THERMAZENE.
ELASE-CHLOROMYCETIN vs THERMAZENE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Elase-Chloromycetin is a combination product containing fibrinolysin and desoxyribonuclease (Elase) for enzymatic debridement, and chloramphenicol (Chloromycetin), a bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Silver sulfadiazine acts by releasing silver ions that bind to microbial DNA and cell membranes, inhibiting bacterial replication and causing cell death. It also has anti-inflammatory effects by modulating cytokine release.
Topical application: Apply thin layer to affected area 2-3 times daily.
1% cream applied topically once or twice daily; for burns, apply 1/16-inch thick layer over entire burn area.
None Documented
None Documented
Chloramphenicol has a terminal elimination half-life of 1.5 to 4.0 hours in adults with normal renal and hepatic function. In neonates, half-life can be prolonged to 24-48 hours, necessitating dose adjustment. Elase has no systemic half-life as it acts locally.
Terminal elimination half-life is approximately 22 hours (range 17–28 h) in patients with normal renal function, enabling twice-daily dosing in most cases.
Chloramphenicol is primarily excreted renally (approximately 90% as inactive metabolites). Fecal excretion accounts for less than 1% of the dose. Biliary elimination is negligible. Elase (fibrinolysin and desoxyribonuclease) is locally degraded and not systemically absorbed, thus its excretion is irrelevant.
Renal: ~65% unchanged; biliary/fecal: ~35% as metabolites and unchanged drug.
Category C
Category C
Topical Antibiotic and Debriding Agent
Topical Antibiotic